|
FDA Wants to Clear 364 Forgotten ANDAs on Eve of GDUFA Passage
The FDA’s Office of Generic Drugs (OGD) appears to be taking the first steps to whittling down its almost 3,000-long ANDA backlog, telling drugmakers it will discard 364 pending generic-drug applications unless told otherwise.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAsFDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone GenericsFDA: More Work May Be Needed to Discourage Anticompetitive PetitionsFDA Sets Higher Than Expected Fiscal 2013 Generic Facility Fees, Payment Due March 4
|
Subscribe
Archives